Drug Type Biosimilar, Monoclonal antibody |
Synonyms Recombinant chimeric anti-TNFα antibody(Zhejiang Hisun Pharmaceutical Co., Ltd.), 重组人鼠嵌合抗肿瘤坏死因子α单抗 (海正药业), HS-626 + [2] |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date China (28 Sep 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02598 | - | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ankylosing Spondylitis | China | 28 Sep 2021 | |
Colitis, Ulcerative | China | 28 Sep 2021 | |
Crohn Disease | China | 28 Sep 2021 | |
Pediatric Crohn's Disease | China | 28 Sep 2021 | |
Psoriasis | China | 28 Sep 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plaque psoriasis | Phase 3 | China | 25 May 2018 |